What question did this study set out to answer?

To review the current state of tuberculosis vaccine development and therapeutic interventions while identifying critical hurdles and prospective strategies to combat drug resistance.

January 22, 2025Molecular BiomedicineOpen Access

Tuberculosis vaccines and therapeutic drug: challenges and future directions

View Full Paper

Ask AI

Bookmark

Authors

YAYajing An RNRuizi Ni ZLZhuang Li

Discussion

Member takes

Overview

Literature review highlights emerging vaccine platforms and novel antimicrobials against drug-resistant tuberculosis, suggesting multi-target strategies are critical to overcome treatment barriers.

Key Points

To review the current state of tuberculosis vaccine development and therapeutic interventions while identifying critical hurdles and prospective strategies to combat drug resistance.
Synthesized contemporary literature on tuberculosis vaccine pipelines, focusing on antigen identification, clinical trials, multi-antigen constructs, and mRNA platforms.
Evaluated current and emerging therapeutics for multidrug-resistant tuberculosis, including bedaquiline, delamanid, and host-directed therapies.
Identified critical barriers to progress, such as bacterial antigen diversity, variable vaccine performance across populations, prolonged treatment regimens, and diagnostic deficiencies.
Highlighted the necessity of future combinatorial approaches, personalized treatment protocols, and antimicrobials targeting novel biological pathways to effectively control drug-resistant strains.

Cite This Study

An et al. (2025) studied this question.

synapsesocial.com/papers/6a6fcd1ba2d7cf2e39c29714 https://doi.org/10.1186/s43556-024-00243-6

View Full Paper

Ask AI

Bookmark

January 22, 2025Molecular BiomedicineOpen Access

Tuberculosis vaccines and therapeutic drug: challenges and future directions

View Full Paper

Ask AI

Bookmark

Authors

YAYajing An RNRuizi Ni ZLZhuang Li

Discussion

Member takes

Overview

Literature review highlights emerging vaccine platforms and novel antimicrobials against drug-resistant tuberculosis, suggesting multi-target strategies are critical to overcome treatment barriers.

Key Points

To review the current state of tuberculosis vaccine development and therapeutic interventions while identifying critical hurdles and prospective strategies to combat drug resistance.
Synthesized contemporary literature on tuberculosis vaccine pipelines, focusing on antigen identification, clinical trials, multi-antigen constructs, and mRNA platforms.
Evaluated current and emerging therapeutics for multidrug-resistant tuberculosis, including bedaquiline, delamanid, and host-directed therapies.
Identified critical barriers to progress, such as bacterial antigen diversity, variable vaccine performance across populations, prolonged treatment regimens, and diagnostic deficiencies.
Highlighted the necessity of future combinatorial approaches, personalized treatment protocols, and antimicrobials targeting novel biological pathways to effectively control drug-resistant strains.

Cite This Study

An et al. (2025) studied this question.

synapsesocial.com/papers/6a6fcd1ba2d7cf2e39c29714 https://doi.org/10.1186/s43556-024-00243-6

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark